<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435174</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-0123, HUM00051141</org_study_id>
    <nct_id>NCT01435174</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients</brief_title>
  <official_title>Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      End-stage renal disease (ESRD) patients often develop cardiovascular complications, and
      cardiovascular disease is the leading cause of death in this population. Ranolazine's
      ability to treat angina without reducing heart rate or blood pressure makes it an important
      option for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose
      pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD
      patients on and off hemodialysis. Results of the proposed study will provide initial dosing
      estimates for a follow-up, multiple-dose pharmacokinetic study in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters of Ranolazine</measure>
    <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QT Interval</measure>
    <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Calculation of the QT interval after receiving a single-dose of ranolazine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>A single dose of two oral ranolazine extended release 500 mg tablets</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pharmacokinetic Blood and Dialysate Sampling</intervention_name>
    <description>Blood samples collected to assess ranolazine plasma and dialysate concentrations.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
    <other_name>PK sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QT Interval</intervention_name>
    <description>Calculation of a QT interval will be performed throughout subject participation.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
    <other_name>QT interval calculation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-74 years of age

          -  Within 50% of ideal body weight and greater than 40 kg

          -  Chronic kidney disease (CKD) stage 5 receiving maintenance hemodialysis for at least
             3 months

          -  Native kidney estimated glomerular filtration rate(GFR) &lt; 10 mL/min

          -  No concurrent illness or evidence of infection

          -  Able to give informed consent

        Exclusion Criteria:

          -  QTc interval &gt; 470 msec at echocardiogram (ECG) obtained within the last 6 months

          -  Concomitant QT-prolonging drugs, major P-gp inhibitors, and CYP3A4 inducers and
             inhibitors including: cyclosporine, rifampin, rifabutin, rifapentine, phenobarbital,
             phenytoin, carbamazepine, St. John's Wort, ketoconazole, itraconazole,
             clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir, quinidine,
             dofetilide, sotalol, amiodarone, erythromycin, thioridazine, ziprasidone,
             haloperidol, trimethoprim/sulfamethoxazole, ciprofloxacin, norfloxacin, levofloxacin,
             moxifloxacin

          -  Pre-study hemoglobin &lt; 9.5 g/dL

          -  Plasma albumin &lt; 2.5 g/dL

          -  Liver disease - exclude subjects with a Child Pugh score of C or higher

          -  Positive pregnancy test

          -  Breastfeeding

          -  Allergy to ranolazine

          -  Participating in another investigational study

          -  Hepatitis B infection due to dialysis isolation requirements

          -  Unstable blood pressure control

          -  Need for routine large fluid removal during dialysis (&gt; 4L)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A Mueller, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 24, 2014</lastchanged_date>
  <firstreceived_date>September 14, 2011</firstreceived_date>
  <firstreceived_results_date>May 21, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Bruce A. Mueller</investigator_full_name>
    <investigator_title>Associate Dean of Academic Affairs</investigator_title>
  </responsible_party>
  <keyword>ranolazine</keyword>
  <keyword>end-stage renal disease</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cardiovascular disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients 18 to 74 with chronic kidney disease stage 5 receiving 3 times weekly maintenance hemodialysis for at least 3 months were considered for study inclusion. Patients had to weigh &gt;40 kilograms, be within 50-150% of their ideal body weight, have an eGFR of &lt;10 mL/min, have no evidence of infection, and be able to give informed consent.</population>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33" lower_limit="20" upper_limit="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters of Ranolazine</title>
        <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
        <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacokinetic Parameters of Ranolazine</title>
            <description>Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine</description>
            <units>mcg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.65" spread="0.27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT Interval</title>
        <description>Calculation of the QT interval after receiving a single-dose of ranolazine</description>
        <time_frame>At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
Ranolazine: A single dose of two oral ranolazine extended release 500 mg tablets
Pharmacokinetic Blood and Dialysate Sampling: Blood samples collected to assess ranolazine plasma and dialysate concentrations.
QT Interval: Calculation of a QT interval will be performed throughout subject participation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Potassium with EKG Changes</sub_title>
                <description>High potassium was determined to be due to needing dialysis and unlikely related to the administration of ranolazine. The subject admitted to drinking more than usual (including fruit juice) and not following renal diet over the weekend.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce A. Mueller</name_or_title>
      <organization>University of Michigan College of Pharmacy</organization>
      <phone>7346154578</phone>
      <email>muellerb@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
